Can Basilea’s Antibiotic Succeed Where Others Have Failed?
Company Looks To Partner Ceftobiprole Ahead Of US Approval
Executive Summary
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.
You may also be interested in...
Basilea Buoyant As Antibiotic Finally Gets US Nod
Sales of the Swiss firm’s Zevtera are set to rocket after the beta-lactam antibiotic got approval from the US Food and Drug Administration. Now Basilea needs to sign up a commercial partner.
Basilea Snaps Up Another Antibiotics Program As Pipeline Swells
The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.